CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 11, 2019--
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its key 2020 investor and analyst event schedule, including Manufacturing & Digital Day, Vaccines Day, Science Day and R&D Day.
Manufacturing & Digital Day - March 4
Moderna will host its first annual Manufacturing & Digital Day on March 4, 2020 at 12:00 p.m. ET at the Company’s Norwood, MA facility. Management and Moderna’s digital partners will discuss the Company’s agile manufacturing strategy and highly automated digital enterprise technology to enable rapid, scalable and sustainable late stage development and commercialization. Management will also discuss the Company’s Corporate Social Responsibility initiatives across 5 priorities: patients, employees, communities in which the Company operates, the environment, and corporate governance and ethics.
Vaccines Day - April 14
The Company will host its first annual Vaccines Day on April 14, 2020 at 8:00 a.m. ET in New York City. This event will focus on Moderna’s broad vaccines development portfolio which includes investigational vaccines to prevent debilitating infectious diseases from being passed from mother to child during pregnancy as well as for the prevention of serious respiratory diseases. Management also plans to discuss its approach to future development of investigational vaccines, its commitment to public health collaborations with foundations and government agencies, and its overall perspective on the significant global commercial opportunity that vaccines provide the Company.
Science Day - June 2
The Company will host its annual Science Day on June 2, 2020 at 8:00 a.m. ET in New York City. This event will focus on the Company’s newest advances from its commitment to basic and applied sciences.
R&D Day - September 17
The Company will host its annual R&D Day at 8:00 a.m. ET on September 17, 2020 in New York City. This event will include presentations from management and key opinion leaders with a focus on Moderna’s clinical development pipeline.
Additional details for each event will be made available later. Live webcasts will be available under “Events & Presentations” in the Investors section of the Moderna website at https://investors.modernatx.com. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. (NASDAQ: AZN) and Merck, Inc. (NASDAQ: MRK), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005159/en/
Source: Moderna, Inc.
Senior Manager, Corporate Communications
Head of Investor Relations